| ￥1600 | |
| Z03702 | |
|
|
|
|
|
|
|
|
|
The GenCRISPR™ Cas9 v1.2 can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges. GenCRISPR™ Cas9 v1.2 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus localization signal (nucleoplasmin NLS) at C-terminal. It has been reported that BPNLS and nucleoplasmin NLS are able to improve the gene editing efficiency. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| Key Features |
High gene
editing efficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: Amino acid is free from additional tagging amino acid. DNA-free: No external DNA added to the system. |
|
gRNA-dependent double-stranded DNA cleavage |
| Source |
Recombinant
Cas9 with a BPNLS at N-terminal and a nucleoplasmin NLS at C-terminal expressed
by E.coli |
| Species |
Streptococcus pyogenes |
| Tag |
Tag-free |
| Molecular Weight |
~160
kDa |
| Concentration |
4 mg/ml |
| Active temperature |
This
Cas9 is active at 37°C. |
| Formulation |
Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1
mM EDTA, 50% glycerol, pH 8.0. |
| Storage & Stability |
This product remains stable for up to 12 months at -20°C. Avoid repeated freeze-thaw
cycles. |
| Appearance |
Clear,
colorless liquid |
| Purity |
≥ 90%
as analyzed by SDS-PAGE |
| Concentration |
4
mg/ml±10% |
| Bioactivity |
≥ 90% |
| Residual DNase |
Non-specific
DNase activity |
| Residual RNase |
Non-specific
RNase activity |
| Endotoxin Level |
≤
100 EU/mg as analyzed by gel clotting method |
A 20 μl reaction in 1 × Cas9 Nuclease Reaction Buffer containing linearized plasmid, gRNA, and Cas9 for 1 hour at 37 °C results in a digestion efficiency of linearized plasmid higher than 90%, as determined by agarose gel electrophoresis. »
Human Jurkat cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.2 (Z03702)+ sgRNA (synthesized from GenScript gene@genscript.com) for human TCRαβ gene knock out by electroporation. After transfection and cell culture, measure the gene editing efficiency. GenCRISPR™ Cas9 v1.2 shows a much high editing efficiency. »
Human T cells were cultured for the test. The cells were transfected with GenCRISPR™ Cas9 v1.2 (Z03702)+ sgRNA (synthesized from GenScript gene@genscript.com) + dsDNA template (synthesized from GenScript gene@genscript.com) for knock in test at TCRαβ site by electroporation. After transfection and cell culture, measure the editing efficiency. »
| References |
1.
Liu, Xinyi, et al. "Improving editing
efficiency for the sequences with NGH PAM using xCas9-derived base
editors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635. 2. Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 3. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846. 2. Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 3. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846. |
